Millendo Therapeutics Inc (MLND) |
|
1.94 -0.13 (-6.28%)
|
03-03 17:03 |
|
Open: |
2.09 |
Pre. Close: |
2.07 |
|
High:
|
2.12 |
Low:
|
1.94 |
|
Volume:
|
752,156 |
Market Cap:
|
37M |
|
|
|
|
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.124 - 2.136 |
2.136 - 2.149 |
|
Low:
|
1.908 - 1.921 |
1.921 - 1.934 |
|
Close:
|
1.917 - 1.938 |
1.938 - 1.962 |
|
Technical analysis |
as of: 2021-03-03 4:42:56 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 2.82 One year: 3.24 |
| Support: |
Support1: 1.85 Support2: 1.54 |
| Resistance: |
Resistance1: 2.42 Resistance2: 2.77 |
| Pivot: |
2.38  |
| Moving Average: |
MA(5): 2.09 MA(20): 2.37
MA(100): 1.92  MA(250): 2.20 |
| MACD: |
MACD(12,26): -0.01 Signal(9): 0.07 |
| Stochastic oscillator: |
%K(14,3): 9.96 %D(3): 11.93 |
| RSI: |
RSI(14): 38.34 |
| 52-week: |
High: 8.42 Low: 1.26 Change(%): -76.3 |
| Average Vol(K): |
3-Month: 67636 10-Days: 48377 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.MLND has closed above bottom band by 6.2%. Bollinger Bands are 82.7% wider than normal. The large width of the bands suggest high volatility as compared to MLND's normal range. The bands have been in this wide range for 3 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Tue, 09 Feb 2021
Millendo Therapeutics - Consensus Indicates Potential 77.8% Upside - DirectorsTalk Interviews
Wed, 03 Feb 2021
Is Millendo Therapeutics Inc (MLND) the Top Pick in the Biotechnology Industry? - InvestorsObserver
Mon, 01 Feb 2021
What is the Market's View on Millendo Therapeutics Inc (MLND) Stock's Price and Volume Trends - InvestorsObserver
Fri, 29 Jan 2021
How Does Millendo Therapeutics Inc (MLND) Stock Rank on Wall Street? - InvestorsObserver
Wed, 06 Jan 2021
Should You Buy Millendo Therapeutics Inc (MLND) Stock After it Is Lower By 20.00% in a Week? - InvestorsObserver
Tue, 05 Jan 2021
Analyst Rating: Will Millendo Therapeutics Inc (MLND) Stock Outperform the Market? - InvestorsObserver
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
19 |
| Shares Float (M) |
15 |
|
% Held by Insiders
|
6.29 |
|
% Held by Institutions
|
41.79 |
|
Shares Short (K)
|
703 |
|
Shares Short P. Month (K)
|
404 |
Stock Financials |
|
EPS
|
-2.348 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
2.060 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-48.5 |
|
Return on Equity (ttm)
|
-98.6 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-2.183 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-37 |
|
Levered Free Cash Flow (M)
|
-19 |
Stock Valuations |
|
PE Ratio
|
-0.83 |
|
PEG Ratio
|
|
|
Price to Book value
|
0.94 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
